Search

Your search keyword '"Suh, Dong-Churl"' showing total 311 results
Start Over Author "Suh, Dong-Churl"
311 results on '"Suh, Dong-Churl"'

1. The evolving value assessment of cancer therapies: Results from a modified Delphi study

Author

Lee, Myrto, Larose, Hugo, Gräbeldinger, Martin, Williams, Jon, Baird, Anne-Marie, Brown, Susan, Bruns, Johannes, Clark, Russell, Cortes, Javier, Curigliano, Giuseppe, Ferris, Andrea, Garrison, Louis P., Gupta, Y.K., Kanesvaran, Ravindran, Lyman, Gary, Pani, Luca, Pemberton-Whiteley, Zack, Salmonson, Tomas, Sawicki, Peter, Stein, Barry, Suh, Dong-Churl, Velikova, Galina, and Grueger, Jens

Published
2024
Full Text
View/download PDF

4. Value based healthcare and Health Technology Assessment for emerging market countries: joint efforts to overcome barriers.

Author

Otte, Maximillian, Dauben, Hans Peter, Ahn, Jeonghoon, Gutierrez Ibarluzea, Iñaki, Drummond, Michael, Simoens, Steven, Kaló, Zoltán, and Suh, Dong-Churl

Abstract

Introduction: This paper summarizes the results from a forum of healthcare experts, academia representatives, and public agency officials from emerging and established market countries on Value-Based Healthcare (VBHC) and Health Technology Assessment (HTA). Presentations from experts provided insights into current developments and challenges, followed by interactive roundtable discussions. Emerging markets have unique healthcare systems, patient populations, resource constraints and needs. Areas covered: Each roundtable explored specific topics including the role of HTA and Real-world evidence (RWE) in healthcare decision-making, challenges in biosimilar value assessment and incorporating non-price criteria reflecting context-related specifications of emerging markets such as the multifaceted nature of value in healthcare decision-making, emphasizing stakeholder perspectives and system complexities. Expert opinion: RWE emerged as important in understanding biosimilar value recognition and decision-making processes, with insights into its applications and challenges. Recommendations were provided for utilizing Multi-Criteria Decision Analysis (MCDA) in pharmaceutical procurement, particularly for off-patent medicines, underscoring the importance of comprehensive evaluation frameworks and adherence to value-based principles. Overall findings suggest avenues for collaboration between industry, academia, and public agencies to address implementation barriers and promote equitable, efficient, and high-quality healthcare systems in emerging markets through public–private partnerships, joint capacity building and training initiatives, and knowledge transfers. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Additional file 1 of Medications influencing the risk of fall-related injuries in older adults: case–control and case-crossover design studies

Author

Jung, Yu-Seon, Suh, David, Kim, Eunyoung, Park, Hee-Deok, Suh, Dong-Churl, and Jung, Sun-Young

Abstract

Additional file 1: Supplementary Table 1. Subgroup analysis of the case-crossover design by CCI (0–1, 2–4, 5 or more). Supplementary Table 2. Sensitivity analysis of the case-crossover design with an additional washout period (control periods: 120–180 and 240–300 days prior to the index date).

Published
2023
Full Text
View/download PDF

35. International Price Comparisons of Anticancer Drugs: A Scheme for Improving Patient Accessibility

Author

Jung, Jae Ho, Kim, Dae Jung, Suh, Kangho, You, Jaeeun, Lee, Je Ho, Joung, Kyung In, Suh, Dong Churl, Jung, Jae Ho, Kim, Dae Jung, Suh, Kangho, You, Jaeeun, Lee, Je Ho, Joung, Kyung In, and Suh, Dong Churl

Abstract

Background: The demand for implementing a new listing scheme to expedite patient access to novel oncology drugs has increased in South Korea. This study was conducted to compare the prices of anticancer drugs between eight countries and to explore the feasibility of a ‘pre-listing and post-evaluation’ scheme to expedite patient access to oncology drugs. Methods: This study included 34 anticancer drugs, which were reimbursed between 1 January 2007 and 31 December 2017. The unit price and sales volume of the study drugs were collected from eight countries and IQVIA data, respectively. The prices were adjusted to estimate the ex-factory prices using the discount/rebate rate suggested by the Health Insurance Review Agency (HIRA). The four price indices of Laspeyres, Paasche, Fisher, and the unweighted index were calculated using the price in each country, the average price, and lowest price among the study countries. Each currency was converted using the currency exchange rate and purchasing power parity (PPP). The budget impact of implementing the proposed pre-listing and post-evaluation scheme on payers was calculated. Results: Based on the currency exchange rate, anticancer drug prices were higher in other countries (index range: 1.05–2.78) compared to Korea. The prices in Korea were similar to countries with the lowest prices. When the PPP was applied, prices were higher in the US, Germany, Italy, and Japan than in Korea (range: 1.10–2.13); however, the prices were lower in the UK, France, and Switzerland than in Korea (range: 0.72–0.99). The financial burden of implementing the pre-listing and post-evaluation scheme was calculated at 0.83% of the total anticancer drug sales value in Korea from 2013–2017. Conclusions: The prices of anticancer drugs in Korea were similar to the lowest prices among the seven other study countries. A pre-listing and post-evaluation scheme should be considered to improve patient access to novel anticancer drugs by reducing the reimburse

Published
2021

40. Factors related to physicians' adoption of electronic prescribing: results from a national survey

Author

Pizzi, Laura T., Suh, Dong-Churl, Barone, Joseph, and Nash, David B.

Subjects
Hospital information systems -- Usage, Medication errors -- Analysis -- Prevention -- Surveys -- Usage -- Technology application, Information storage and retrieval systems -- Hospitals, Prescription writing -- Technology application -- Usage -- Surveys -- Analysis, Physicians -- Practice -- Surveys, Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Health, Technology application, Practice, Prevention, Usage, Analysis, Surveys
Abstract

Electronic prescribing (E-RX) is a component of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA). The objective of this study was to identify factors related to physicians' [...]

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results